New RSV vaccine trial launches: is this the shot We've been waiting for?
NCT ID NCT07418229
First seen Feb 22, 2026 · Last updated May 24, 2026 · Updated 15 times
Summary
This early-stage trial tests a new RSV mRNA vaccine for safety in 60 healthy adults aged 18 and older. The vaccine aims to prevent respiratory syncytial virus (RSV) infection. Participants will receive either the vaccine or a placebo, and researchers will monitor for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Qinxian Center for Disease Control and Prevention
Changzhi, Shanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.